Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study

Zhong, WZ; Chen, KN; Chen, C; Gu, CD; Wang, J; Yang, XN; Mao, WM; Wang, Q; Qiao, GB; Cheng, Y; Xu, L; Wang, CL; Chen, MW; Kang, XZ; Yan, WP; Yan, HH; Liao, RQ; Yang, JJ; Zhang, XC; Zhou, Q; Wu, YL

Wu, YL (reprint author), Guangdong Acad Med Sci, Guangzhou 510080, Guangdong, Peoples R China.; Wu, YL (reprint author), Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou 510080, Guangdong, Peoples R China.

JOURNAL OF CLINICAL ONCOLOGY, 2019; 37 (25): 2235

Abstract

PURPOSE To assess the benefits of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as neoadjuvant/adjuvant therapies in locally adva......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索